Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease Read more
Pulse Seismic Inc. Reports 2024 Financial Results and Declares Regular and Special Dividends Read more
Bird Construction Inc. Announces Release Date and Conference Call for 2024 Fourth Quarter and Annual Financial Results Read more
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 Read more